VanEck Biotech ETF
BBH
82 hedge funds and large institutions have $75.4M invested in VanEck Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 28 reducing their positions, and 14 closing their positions.
654% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $241K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 82 → 82 (0)
9.71% less ownership
Funds ownership: 26.63% → 16.92% (-9.7%)
43% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 28
58% less capital invested
Capital invested by funds: $179M → $75.4M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
Aspiriant LLC
Los Angeles,
California
|
+$1.43M |
| 2 |
PA
Pinnacle Associates
New York
|
+$949K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$773K |
| 4 |
PSF
Pacific Sun Financial
Los Angeles,
California
|
+$702K |
| 5 |
Goldman Sachs
New York
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$77.8M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$6.22M |
| 3 |
CG
Colony Group
Boston,
Massachusetts
|
-$4.9M |
| 4 |
TC
Trust Company
Manhattan,
Kansas
|
-$4.33M |
| 5 |
WI
WBI Investments
Red Bank,
New Jersey
|
-$2.61M |
BBH Hedge Fund Activity: Q1 2018 in Review
82 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2018, worth a combined $75.4M — down 58% from $179M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BBH positions and 14 closed out — a net gain of 1 holder — while 16 added to existing stakes and 28 trimmed.
The largest buyer was Aspiriant LLC, opening a new position worth an estimated $1.43M. The largest seller was AllianceBernstein, exiting entirely with an estimated $77.8M sold.
- 82 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $75.4M of VanEck Biotech ETF stock for Q1 2018, down 58% quarter-over-quarter.
- 15 funds opened new VanEck Biotech ETF positions in Q1 2018 and 14 closed out, a net change of +1 holder.
- The largest VanEck Biotech ETF buyer in Q1 2018 was Aspiriant LLC, an estimated $1.43M added.
- The largest VanEck Biotech ETF seller in Q1 2018 was AllianceBernstein, an estimated $77.8M sold.
Based on aggregated 13F filings for Q1 2018.